Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

In this expert perspective from Retina 2026, Baruch D. Kuppermann, MD, PhD, discusses positive data from real-world studies ...

Fluocinolone implants can slow diabetic retinopathy and delay proliferation in patients with diabetic macular edema, researchers say. Compared with antivascular endothelial growth factor (anti-VEGF) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes did not have higher risk for ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Brolucizumab ...

Credit: Regeneron. Eylea HD is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose vial containing 8mg of aflibercept. The Food and Drug Administration (FDA) has ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ® ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema (DME), which is the ...

The Global Diabetic Macular Edema Market is experiencing significant growth driven by rising diabetes prevalence and technological advancements in retinal diagnostics like OCT and AI-enabled imaging.